NAD+ and NMN for Neuropathy: Impressive in Mice, Untested in People

Peripheral neuropathy — the numbness, burning, and stabbing pain of damaged nerves, most often from diabetes or chemotherapy — is a problem with few good treatments. So when laboratory studies report that NAD+ precursors like NMN and nicotinamide riboside (NR) can reverse nerve damage, it's easy to see why supplement marketing seizes on it. The mechanism here is unusually compelling, too: NAD+ isn't just a generic "energy molecule" in nerves, it sits at the heart of a dedicated axon-survival program. That makes neuropathy one of the more scientifically interesting NAD+ stories.

It also makes it one of the most important to frame honestly, because the entire impressive body of evidence is in animals and cells. There is no human trial showing NMN or NR treats neuropathy in people. This page walks through why the biology is genuinely exciting, exactly what was shown (and in which species), and why "reversed neuropathy in mice" must not be read as "will fix your neuropathy."

Why NAD+ is mechanistically central to nerve survival

Most NAD+ claims rest on the vague idea that more NAD+ means more cellular energy. In nerves, the link is far more specific and well-characterized. When an axon is injured, it self-destructs through a controlled program called Wallerian degeneration — and the trigger for that program is a collapse in local NAD+. The enzyme SARM1, the central executioner of axon death, was shown to be itself an NAD+-cleaving enzyme: when activated, it chews up NAD+, and that NAD+ destruction is what drives the axon to degenerate ¹. In other words, keeping NAD+ levels up inside a stressed nerve is, mechanistically, a way to hold off the very self-destruct switch that causes the nerve to die back.

That's why NAD+ precursors are a rational thing to test in neuropathy specifically — far more so than in most conditions they're marketed for. The hypothesis isn't hand-waving; it targets a defined molecular pathway. NAD+ also declines with age and metabolic stress in tissue generally ², which dovetails with why diabetic and aging nerves might be NAD+-starved.

What was actually shown — and in whom

Here is the impressive part, stated precisely. In a 2024 study, NAD+ precursors reversed established experimental diabetic neuropathy in mice, restoring nerve function and mitochondrial health ³. An earlier study from the same group showed NAD+ precursors repaired mitochondrial function and prevented experimental diabetic neuropathy in diabetic animals ⁴, building on a broader understanding of how mitochondrial failure drives diabetic nerve damage ⁵. Separately, nicotinamide riboside was shown to oppose both type 2 diabetes and neuropathy in mice ⁶, and to improve diabetic enteric (gut) neuropathy by protecting the myenteric plexus in rats ⁷.

The chemotherapy-neuropathy data are similar in strength and species. NR relieved both the pain-sensitivity and the aversive, emotional dimensions of paclitaxel-induced peripheral neuropathy in female rats ⁸, and pharmacologically boosting the NAD+ salvage pathway protected neurons from chemotherapy-induced degeneration in cell and animal models ⁹.

Read that list again and notice what every single entry has in common: mice, rats, or cultured neurons. Not one is a human therapy trial.

The human gap is total — and that matters

This is the honest crux. No randomized controlled trial has shown that NMN or NR treats peripheral neuropathy in people — not diabetic neuropathy, not chemotherapy-induced neuropathy, not any other kind. The human NMN trials that do exist studied other endpoints entirely: the best-known controlled NMN study in humans measured muscle insulin sensitivity in prediabetic women and did not assess nerve function or neuropathy at all ¹⁰. So the marketing chain "NMN reverses diabetic neuropathy" quietly substitutes a mouse result for a human one.

That substitution is dangerous in neuropathy for concrete reasons. Animal-to-human translation in neuropathy is notoriously poor — a long graveyard of compounds reversed diabetic or chemo neuropathy in rodents and then failed in human trials. Rodent studies use controlled genetics, short timelines, and often prevent or treat very recent damage, whereas human neuropathy is chronic, multifactorial, and frequently advanced by the time it's diagnosed. And the doses that work in a 30-gram mouse cannot be naively scaled to a person. None of this means the precursors can't work in humans — it means we genuinely do not know, and anyone claiming otherwise is ahead of the evidence.

What this means if you have neuropathy

• •The mechanism is real and specific: NAD+ depletion via SARM1 drives axon self-destruction, so maintaining NAD+ is a logical nerve-protection strategy ¹.
• •The preclinical data are genuinely strong — NMN and NR reversed or prevented diabetic and chemo neuropathy across multiple mouse and rat studies ³⁴⁶⁷⁸⁹.
• •The human evidence is zero: no controlled trial has tested NMN or NR for neuropathy in people; the human NMN trials measured other endpoints ¹⁰.
• •Neuropathy has real, established medical management — so NMN or NR is not a substitute for seeing a clinician, controlling blood sugar in diabetes, or using proven symptomatic treatments.

The fair verdict: NAD+ precursors for neuropathy are a promising preclinical hypothesis worth watching for human trials, not a treatment you can rely on today. If you're considering supplementing anyway, do it as an adjunct discussed with your clinician — not as a replacement for care — and understand the broader picture first. For where NAD+ supplementation is genuinely supported versus merely hoped-for, see our pillar guide to NAD+ therapy evidence, the parallel "promising-but-early" story in NAD+ (NR) for Parkinson's, the side effects to know before high-dose precursors, and how products and providers compare on our NAD+ rankings hub.